InCephalo appoints Dr. Lorenz Mayr as new Chair

Allschwil, Switzerland, 20th March 2024 - InCephalo , a preclinical stage company pioneering its Compartment Lock technology for local treatment of brain cancer, announced today the appointment of Lorenz Mayr as the Chair of its Board of Directors.

Dr MBA Carlo Bertozzi, CEO and departing Chair of InCephalo, commented: “This is an exciting time at InCephalo, and we're thrilled to welcome Lorenz to our team. I am personally convinced that Lorenz's dynamic presence, strategic vision, and broad network will lead to impactful advancements, pushing us to make further progress for those suffering from brain cancer. His distinguished background in drug discovery underscores our unwavering commitment and dedication to fulfilling the needs of patients with brain cancer.

Lorenz is a highly respected biopharmaceutical executive with extensive experience over the last 30 years in drug discovery, technology and innovation, business growth and financing strategy.

He currently serves on the Board of Directors at Phoremost (Cambridge, UK), Mogrify (Cambridge, UK), FundaMental Pharma (Heidelberg, Germany), the Scientific Advisory Board of Fraunhofer IGB & IPA (Stuttgart, Germany), Fraunhofer IZI (Leipzig, Germany), SaxoCell (Leipzig & Dresden, Germany), The Francis Crick Institute (London, UK), Medicines Discovery Catapult (Alderley Park, UK), LenioBio (Düsseldorf, Germany) and SensibleBio (Oxford, UK): He also works as Senior Healthcare Advisor to EQT Investments (Stockholm/Sweden).

Most recently, Lorenz was CEO of Vector BioPharma (Basel, Switzerland). He has held various other senior executive roles in companies such as Bayer, Novartis, AstraZeneca, GE Healthcare and Syncona. Previously, he was Chief Technology Officer at GE Healthcare Life Sciences, where he was responsible for R&D strategy and innovation across all life sciences business areas. Lorenz has extensive global experience in pharmaceutical R&D, including positions as Vice President & Global Head at AstraZeneca and Executive Director at Novartis and Bayer Pharmaceuticals. Lorenz obtained a Ph.D. in Biochemistry & Biophysics at University of Bayreuth in 1993 and went on to pursue a Postdoc at the Massachusetts Institute of Technology in 1993-1995.

Dr Lorenz Mayr, new Chair of InCephalo, commented: “InCephalo AG is pioneering the treatment of brain cancer by the development of novel technologies to enhance the efficacy and safety of biological agents used for effective treatments in the brain. The Compartment Lock technology developed by InCephalo AG is poised to improve the lives of patients living with brain tumors and I am pleased to join the company as a Chair at such an exciting phase in its journey.”

For further information, please contact: 

InCephalo AG

Dr MBA Carlo Bertozzi, CEO

Email: bertozzi@incephalo.com

About InCephalo AG

InCephalo develops exclusively local treatments for neurological diseases, with a focus on cancers in the brain (primary brain cancers as well as secondary brain cancers). The proprietary Compartment Lock technology, also called C-Lock, retains biologics, that are applied locally behind the blood brain barrier, in the central nervous system (CNS) and once they leave the CNS, degrades them rapidly in the systemic compartment. Thereby it significantly improves local CNS therapy, a challenging task with regards to achieving high local concentration (for efficacy) and low systemic footprint (to reduce potential side effects). Especially the peripheral side effects still limit various promising candidates for the treatment of brain cancer or other neurological diseases.